Improving the efficiency of drug approvals in MDS

In recent years, the treatment and management of myelodysplastic syndromes (MDS) has improved, and several clinical trials are investigating novel combinations and agents with the aim of providing more options for patients. Due to the heterogeneity of this disease, there are several challenges with treating MDS, and a need to improve the availability of therapeutic agents.

In this podcast, leading experts Hetty Carraway, MD, Cleveland Clinic, Cleveland, OH, Justin Taylor, MD, Sylvester Comprehensive Cancer Center, Miami, FL, Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, and Olatoyosi Odenike, MD, UChicago Medicine, Chicago, IL, share their thoughts on how to improve the efficiency of drug approvals in MDS. The experts cover several interesting topics, including the challenges associated with treating high-risk disease, novel targets of interest, and more. This discussion took place at the 1st International Workshop on Myelodysplastic Syndromes (iwMDS) held in Miami, FL.